Table 5 Hazard ratios for overall survival in the joint subgroups with platinum-based chemotherapy
From: Prognostic value of localization of epidermal growth factor receptor in lung adenocarcinoma
tEGFR/mutant | Number | Median (m)a | Unadjusted HR (95% CI) | p | Adjusted HRb (95%CI) | p |
|---|---|---|---|---|---|---|
tEGFR− mutant− | 11 | 18.2 | 1.0 | 1.0 | ||
tEGFR+ mutant− | 10 | 34.7 | 0.33 (0.12~ 0.92) | 0.029 | 0.36 (0.13~ 1.02) | 0.055 |
tEGFR− mutant+ | 10 | 29.5 | 0.65 (0.41~ 1.04) | 0.070 | 0.64 (0.39~ 1.05) | 0.076 |
tEGFR+ mutant+ | 21 | 25.9 | 0.74 (0.56~ 0.97) | 0.033 | 0.83 (0.59~ 1.15) | 0.260 |